Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hodgkin Disease 37 Lymphoma 27 Urinary Bladder Neoplasms 9 Melanoma 7 Carcinoma, Non-Small-Cell Lung 4 Urethral Neoplasms 3 Prostatic Neoplasms 3 Lung Neoplasms 3 Skin Neoplasms 2 Oligodendroglioma 2 Neurofibromatosis 1 2 Neoplasms 2 Lymphoma, Large-Cell, Anaplastic 2 Leukemia 2 HIV Infections 2 Glioma 2 Central Nervous System Neoplasms 2 Brain Neoplasms 2 Astrocytoma 2 Uterine Cervical Neoplasms 1 Urothelial Carcinoma of the Bladder 1 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Survival Without Progression 1 Sarcoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Optic Nerve Glioma 1 Neurofibroma, Plexiform 1

Interventions

Vinblastine 1 Methotrexate 1 Cyclophosphamide 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Survival Without Progression × Vinblastine × Clear all

NCT01285817 2023-03-13

SFCE METRO 01

Assistance Publique Hopitaux De Marseille

Phase 2 Completed

Survival Without Progression

Data powered by HemOnc (CC BY 4.0) Colophon ⚡